首页> 美国卫生研究院文献>The Journal of Clinical Investigation >Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene.
【2h】

Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene.

机译:对29个对甲状腺激素具有普遍性和垂体性抵抗力的亲属的遗传分析。鉴定甲状腺激素受体β基因中的13个新突变。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Resistance to thyroid hormone (RTH), with elevated serum free thyroid hormones and nonsuppressed thyrotropin levels, is either relatively asymptomatic, suggesting a generalized disorder (GRTH) or associated with thyrotoxic features, indicating possible selective pituitary resistance (PRTH). 20 GRTH and 9 PRTH cases, sporadic or dominantly inherited, were analyzed. Affected individuals were heterozygous for single nucleotide substitutions in the thyroid hormone receptor beta gene, except for a single case of a seven nucleotide insertion. With one exception, the corresponding 13 novel and 7 known codon changes localized to and extended the boundaries of two mutation clusters in the hormone-binding domain of the receptor. 15 kindreds shared 6 different mutations, and haplotype analyses of the mutant allele showed that they occurred independently. The majority (14 out of 19) of the recurrent but a minority (1 out of 10) of unique mutations were transitions of CpG dinucleotides. Mutant receptor binding to ligand was moderately or severely impaired and did not correlate with the magnitude of thyroid dysfunction. There was no association between clinical features and the nature or location of a receptor mutation. These observations suggest that GRTH and PRTH are phenotypic variants of the same genetic disorder, whose clinical expression may be modulated by other non-mutation-related factors.
机译:对甲状腺激素(RTH)的抵抗,血清游离甲状腺激素水平升高和促甲状腺激素水平未抑制,相对无症状,表明是全身性疾病(GRTH)或与甲状腺毒性有关,表明可能存在选择性的垂体抵抗(PRTH)。分析了20例GRTH和9例PRTH病例,这些病例是散发性或显性遗传的。受影响的个体是甲状腺激素受体β基因中单核苷酸取代的杂合子,只有一个插入七个核苷酸的情况。除了一个例外,相应的13个新颖的密码子变化和7个已知的密码子变化位于受体的激素结合域中,并扩展了两个突变簇的边界。 15个亲戚共有6个不同的突变,突变等位基因的单倍型分析表明它们独立发生。大部分(19例中有14例)复发,而少数(10例中有1例)独特突变是CpG二核苷酸的转变。突变受体与配体的结合受到中度或严重损害,并且与甲状腺功能障碍的程度无关。临床特征与受体突变的性质或位置之间没有关联。这些观察结果表明GRTH和PRTH是同一遗传性疾病的表型变异,其临床表达可能受其他非突变相关因素的调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号